A. Björk

869 total citations
23 papers, 705 citations indexed

About

A. Björk is a scholar working on Cellular and Molecular Neuroscience, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, A. Björk has authored 23 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 7 papers in Pathology and Forensic Medicine and 6 papers in Physiology. Recurrent topics in A. Björk's work include Neurotransmitter Receptor Influence on Behavior (8 papers), Vitamin D Research Studies (5 papers) and Salivary Gland Disorders and Functions (5 papers). A. Björk is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (8 papers), Vitamin D Research Studies (5 papers) and Salivary Gland Disorders and Functions (5 papers). A. Björk collaborates with scholars based in Sweden, United States and Australia. A. Björk's co-authors include M.F. Lankford, R.D. Myers, Marie Wahren‐Herlenius, Johannes Mofors, Erik Christensson, R.D. Myers, Jonatan Leffler, Jessy J. Alexander, Richard J. Quigg and Anna M. Blom and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

A. Björk

23 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Björk Sweden 17 211 195 177 153 131 23 705
Futoshi Yoshida Japan 16 69 0.3× 84 0.4× 93 0.5× 144 0.9× 74 0.6× 32 689
Parayil Sankaran Bindu India 19 170 0.8× 192 1.0× 386 2.2× 24 0.2× 63 0.5× 92 1.1k
S Nakazawa Japan 22 82 0.4× 166 0.9× 415 2.3× 92 0.6× 65 0.5× 51 1.2k
Deon Wolpowitz United States 9 67 0.3× 223 1.1× 250 1.4× 60 0.4× 216 1.6× 17 826
V. Argentiero Italy 9 189 0.9× 79 0.4× 109 0.6× 86 0.6× 70 0.5× 16 523
Wolfgang Rabl Germany 16 78 0.4× 84 0.4× 801 4.5× 65 0.4× 169 1.3× 23 2.0k
JM Theler Switzerland 9 109 0.5× 89 0.5× 391 2.2× 92 0.6× 54 0.4× 9 768
David Coman Australia 20 302 1.4× 43 0.2× 583 3.3× 79 0.5× 51 0.4× 79 1.2k
R. Reñé Spain 14 118 0.6× 241 1.2× 160 0.9× 65 0.4× 56 0.4× 27 1.2k
Vanessa Ramírez United States 16 96 0.5× 30 0.2× 239 1.4× 92 0.6× 98 0.7× 26 986

Countries citing papers authored by A. Björk

Since Specialization
Citations

This map shows the geographic impact of A. Björk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Björk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Björk more than expected).

Fields of papers citing papers by A. Björk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Björk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Björk. The network helps show where A. Björk may publish in the future.

Co-authorship network of co-authors of A. Björk

This figure shows the co-authorship network connecting the top 25 collaborators of A. Björk. A scholar is included among the top collaborators of A. Björk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Björk. A. Björk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Björk, A., Johannes Mofors, & Marie Wahren‐Herlenius. (2020). Environmental factors in the pathogenesis of primary Sjögren's syndrome. Journal of Internal Medicine. 287(5). 475–492. 57 indexed citations
2.
Mofors, Johannes, Elizabeth V. Arkema, A. Björk, et al.. (2019). Infections increase the risk of developing Sjögren's syndrome. Journal of Internal Medicine. 285(6). 670–680. 22 indexed citations
3.
Björk, A., Dan Mellström, Claes Ohlsson, et al.. (2018). Haplotypes in the CYP2R1 gene are associated with levels of 25(OH)D and bone mineral density, but not with other markers of bone metabolism (MrOS Sweden). PLoS ONE. 13(12). e0209268–e0209268. 6 indexed citations
4.
Björk, A., Eva Ribom, Gunnar Johansson, et al.. (2018). Variations in the vitamin D receptor gene are not associated with measures of muscle strength, physical performance, or falls in elderly men. Data from MrOS Sweden. The Journal of Steroid Biochemistry and Molecular Biology. 187. 160–165. 9 indexed citations
5.
Aqrawi, Lara A., A. Björk, Juliana Imgenberg‐Kreuz, et al.. (2018). Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing. Clinical & Experimental Immunology. 192(3). 259–270. 19 indexed citations
6.
Imgenberg‐Kreuz, Juliana, Johanna K. Sandling, A. Björk, et al.. (2018). Transcription profiling of peripheral B cells in antibody‐positive primary Sjögren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scandinavian Journal of Immunology. 87(5). e12662–e12662. 49 indexed citations
7.
Martin, Myriam, Jonatan Leffler, Jennifer Mytych, et al.. (2016). Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes. Cell Death and Differentiation. 23(5). 903–911. 99 indexed citations
8.
9.
Пили, Роберто, Michael Häggman, Walter M. Stadler, et al.. (2010). A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 28(15_suppl). 4510–4510. 16 indexed citations
10.
Bratt, Ola, Michael Häggman, Göran Ahlgren, et al.. (2009). Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer. 101(8). 1233–1240. 58 indexed citations
11.
Björk, A., Per Venge, & Christer Peterson. (2000). Measurements of ECP in serum and the impact of plasma coagulation. Allergy. 55(5). 442–448. 26 indexed citations
12.
Lankford, M.F., A. Björk, & R.D. Myers. (1996). Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats. Alcohol. 13(4). 399–404. 17 indexed citations
13.
Björk, A., et al.. (1996). The mixed receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Alcohol. 13(5). 521–527. 8 indexed citations
14.
Björk, A., Orvar Eeg‐Olofsson, P. Svendsen, Ulf Moström, & Luigi Pellettieri. (1994). Endovascular treatment of a spinal arteriovenous malformation in a 21‐month‐old boy. Acta Paediatrica. 83(12). 1326–1331. 4 indexed citations
15.
Björk, A., Erik Christensson, Bengt E. Gustafsson, et al.. (1994). In the search for a novel class of antipsychotic drugs: preclinical pharmacology of FG5803, a 1-piperazinecarboxamide derivative.. Journal of Pharmacology and Experimental Therapeutics. 271(3). 1338–1347. 3 indexed citations
16.
Myers, R.D., M.F. Lankford, & A. Björk. (1993). 5-HT2 receptor blockade by amperozide suppresses ethanol drinking in genetically preferring rats. Pharmacology Biochemistry and Behavior. 45(3). 741–747. 41 indexed citations
17.
Singh, Gurpreet, Gerhard W. Kalmus, A. Björk, & R.D. Myers. (1993). Alcohol drinking in rats is attenuated by the mixed 5-HT1 agonist/5-HT2 antagonist FG 5893. Alcohol. 10(3). 243–248. 25 indexed citations
18.
Myers, R.D., M.F. Lankford, & A. Björk. (1993). Irreversible suppression of alcohol drinking in cyanamide-treated rats after sustained delivery of the 5-HT2 antagonist amperozide. Alcohol. 10(2). 117–125. 38 indexed citations
19.
Myers, R.D., M.F. Lankford, & A. Björk. (1992). Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide. Pharmacology Biochemistry and Behavior. 43(3). 661–667. 47 indexed citations
20.
Christensson, Erik & A. Björk. (1990). Amperozide: A new pharmacological approach in the treatment of schizophrenia. Pharmacology & Toxicology. 66(s1). 5–7. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Futoshi Yoshida Breakdown of academic impact, for papers by Parayil Sankaran Bindu Breakdown of academic impact, for papers by S Nakazawa Breakdown of academic impact, for papers by Deon Wolpowitz Breakdown of academic impact, for papers by V. Argentiero Breakdown of academic impact, for papers by Wolfgang Rabl Breakdown of academic impact, for papers by JM Theler Breakdown of academic impact, for papers by David Coman Breakdown of academic impact, for papers by R. Reñé Breakdown of academic impact, for papers by Vanessa Ramírez
Rankless by CCL
2026